<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Individuals with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> face an increased risk of developing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and would benefit from early chemopreventive intervention </plain></SENT>
<SENT sid="1" pm="."><plain>Results from preclinical studies in the mouse model of <z:chebi fb="0" ids="34674">dextran sulfate</z:chebi> <z:chebi fb="199" ids="26708">sodium</z:chebi>-induced <z:hpo ids='HP_0002583'>colitis</z:hpo> demonstrate that flat and polypoid <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:mpath ids='MPATH_589'>dysplasias</z:mpath> arise via distinct genetic pathways, impacted by the allelic status of p53 </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, flat and polypoid <z:mpath ids='MPATH_589'>dysplasias</z:mpath> vary in their response to induction by the heterocyclic <z:chebi fb="39" ids="32952">amine</z:chebi> 2-amino-3-methylimidazo[4,5-f]<z:chebi fb="0" ids="17362">quinoline</z:chebi> (IQ) and inhibition by <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi>, a common therapy for the maintenance of <z:hpo ids='HP_0002583'>colitis</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>These data suggest that use of combination therapy is essential for the optimal inhibition of <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>